First Citizens Bank & Trust Co. Buys 208 Shares of Amgen Inc. (NASDAQ:AMGN)

First Citizens Bank & Trust Co. boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 5.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,033 shares of the medical research company’s stock after buying an additional 208 shares during the quarter. First Citizens Bank & Trust Co.’s holdings in Amgen were worth $1,025,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Arden Trust Co lifted its holdings in Amgen by 8.7% during the third quarter. Arden Trust Co now owns 9,587 shares of the medical research company’s stock valued at $2,437,000 after purchasing an additional 768 shares in the last quarter. Vigilant Capital Management LLC grew its stake in shares of Amgen by 8.3% during the 3rd quarter. Vigilant Capital Management LLC now owns 3,260 shares of the medical research company’s stock worth $829,000 after purchasing an additional 250 shares during the period. Diversified Trust Co grew its stake in shares of Amgen by 12.5% during the 3rd quarter. Diversified Trust Co now owns 20,159 shares of the medical research company’s stock worth $5,124,000 after purchasing an additional 2,246 shares during the period. Cambridge Advisors Inc. grew its stake in shares of Amgen by 0.3% during the 3rd quarter. Cambridge Advisors Inc. now owns 25,248 shares of the medical research company’s stock worth $6,417,000 after purchasing an additional 71 shares during the period. Finally, Coastline Trust Co grew its stake in shares of Amgen by 2.3% during the 3rd quarter. Coastline Trust Co now owns 22,994 shares of the medical research company’s stock worth $5,844,000 after purchasing an additional 510 shares during the period. Institutional investors own 75.23% of the company’s stock.

Shares of AMGN stock opened at $235.72 on Friday. The firm has a market cap of $138.06 billion, a P/E ratio of 19.26, a PEG ratio of 2.11 and a beta of 0.81. Amgen Inc. has a 1-year low of $177.05 and a 1-year high of $264.97. The company has a debt-to-equity ratio of 3.20, a current ratio of 2.18 and a quick ratio of 1.81. The firm’s 50-day simple moving average is $246.43 and its 200-day simple moving average is $237.88.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, July 28th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.81 by $0.44. The firm had revenue of $6.21 billion during the quarter, compared to the consensus estimate of $6.19 billion. Amgen had a net margin of 30.04% and a return on equity of 91.98%. The company’s revenue was up 5.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.97 EPS. Analysts expect that Amgen Inc. will post 15.66 earnings per share for the current fiscal year.

In related news, Director R Sanders Williams sold 250 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $242.95, for a total transaction of $60,737.50. Following the completion of the sale, the director now owns 5,159 shares of the company’s stock, valued at approximately $1,253,379.05. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ronald D. Sugar sold 1,000 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $241.02, for a total transaction of $241,020.00. In the last three months, insiders have sold 2,250 shares of company stock valued at $561,548. Corporate insiders own 0.36% of the company’s stock.

AMGN has been the topic of a number of recent analyst reports. Wells Fargo & Company upped their price target on shares of Amgen from $237.00 to $247.00 and gave the stock an “in-line” rating in a research note on Wednesday, July 29th. Oppenheimer increased their price objective on shares of Amgen from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Tuesday, October 6th. Jefferies Financial Group increased their price objective on shares of Amgen from $285.00 to $300.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. SunTrust Banks increased their price objective on shares of Amgen from $254.00 to $268.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Finally, Barclays increased their price objective on shares of Amgen from $245.00 to $250.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 29th. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and fifteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $255.08.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease.

Read More: Quiet Period Expirations

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.